Our team pairs scientific assessment of clinical pharma assets with deal sourcing and investor relationship management for our fund. We run translational diligence in-house and engage with assets on their scientific and clinical merits before any capital decision.
Seasoned pharma/biotech professional with extensive background in drug development and technical operations. Pioneered biosimilars, vaccines, gene therapies, and orphan drugs. Skilled in selling and acquiring highly complex technologies and products, including those relevant for the CDMO industry. Adept at attracting customers, in- and out-licensing, due diligence, fundraising, and investing. Advisor to a Venture Capital Fund, a Family Office and a Boutique Investment Bank. Managed large capital investment programs from planning to new site commissioning. PhD in Organic Chemistry.
Project Integrator of BioNTech’s project Lightspeed, the world’s fastest development ever of a preventive vaccine, saving millions of lives, preventing millions of hospitalizations. Major contributor to five products reaching market across diverse therapeutic areas. Expertise in biopharmaceutical R&D strategy, interdisciplinary team leadership, and program/portfolio management & execution. Background combines scientific and commercial insights with program execution from preclinical to launch. PhD in Organic Chemistry. Advises on how to convert a good plan into even better project execution. Committed to initiatives bringing new treatments to patients and preventive vaccines to people in need – as quickly as possible.
